Premium
Midostaurin abrogates CD 33‐directed Uni CAR and CD 33‐ CD 3 bispecific antibody therapy in acute myeloid leukaemia
Author(s) -
Fasslrinner Frederick,
Arndt Claudia,
Koristka Stefanie,
Feldmann Anja,
Altmann Heidi,
von Bonin Malte,
Schmitz Marc,
Bornhäuser Martin,
Bachmann Michael
Publication year - 2019
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/bjh.15975
Subject(s) - midostaurin , immunotherapy , cd33 , cancer research , medicine , chimeric antigen receptor , antigen , tyrosine kinase , immunology , t cell , myeloid , antibody , myeloid leukemia , stem cell , immune system , biology , receptor , cd34 , genetics
Summary Combinatory therapeutic approaches of different targeted therapies in acute myeloid leukaemia are currently under preclinical/early clinical investigation. To enhance anti‐tumour effects, we combined the tyrosine kinase inhibitor ( TKI ) midostaurin and T‐cell mediated immunotherapy directed against CD 33. Clinically relevant concentrations of midostaurin abrogated T‐cell mediated cytotoxicity both after activation with bispecific antibodies and chimeric antigen receptor T cells. This information is of relevance for clinicians exploring T‐cell mediated immunotherapy in early clinical trials. Given the profound inhibition of T‐cell functionality and anti‐tumour activity, we recommend specific FLT 3 TKI s for further clinical testing of combinatory approaches with T‐cell based immunotherapy.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom